DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/4622
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBittencourt, Augusto Arcemiro-
dc.date.available2023-03-09-
dc.date.available2023-03-30T13:50:04Z-
dc.date.issued2022-09-15-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/4622-
dc.description.abstractChronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome (Ph). The management and treatment of patients with CML should be carried out by a multidisciplinary team, including a dental surgeon, whose knowledge of the oral condition profile of these patients becomes important for a better performance in promoting their oral health and consequently also impacting directly or indirectly. indirectly on the quality of life of these patients. Objective: To evaluate the oral health status and quality of life of patients with CML diagnosed at a hematological referral center in Amazonas. Methodology: This is a clinical, cross-sectional descriptive/analytical study that evaluated oral manifestations (OM), DMFT, plaque index (PI), probing depth (PD), Clinical attachment loss (CAL), bleeding on probing (BoP), periodontal diagnosis and oral health-related quality of life (OHIP-14), in patients with CML up to 3 years of imatinib use. Results: A total of 36 patients were evaluated, 52.8% of whom were male, the median age was 57,5 years, 94% had basic education and 72.2% had an income ≤ 239 dollar. The frequency of OM was 5.5% (n=2), being an ulcerated lesion and a pedicular lesion, DMFT index: 9,99, being 17% (n=6) of the total edentulous patients (17%) and 77.7% with dental caries disease (n=28). Of the patients subject to periodontal evaluation (n=30), the following results were observed: PI: 57.5% (±27.37), CAL 3.10 mm (± 0 .35), PD 2.13mm (± 0.28), BoP: 49.4% (±28.92), and predominantly diagnosis of gingivitis 83.3%, being 80% generalized gingivitis and 71.4% with reduced periodontium. The assessment of the impact of weak OHIP-14 on quality of life at 8.9% (n=32). Conclusion: The condition of patients with CML using imatinib up to 3 years was satisfactory considering the high caries and dental caries, although a low frequency of tissue changes that indicate the need for surveillance in this study, which indicates the need for dental surveillance in this populationpt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSaúde bucalpt_BR
dc.subjectLeucemia Mieloide Crônicapt_BR
dc.subjectÍndice CPODpt_BR
dc.subjectPeriodontiapt_BR
dc.subjectQualidade de vidapt_BR
dc.subjectChronic myeloid leukemiapt_BR
dc.titleCondição de saúde bucal e qualidade de vida de pacientes com Leucemia Mieloide Crônica em um Cenro de Referência em Hematologia no Amazonaspt_BR
dc.title.alternativeOral health condition and quality of life of patients with Chronic Myeloid Leukemia in a Hematology Reference Center in Amazonaspt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2023-03-30T13:50:04Z-
dc.contributor.advisor-co1Fraiji, Nelson Abrahim-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/5204063085335824pt_BR
dc.contributor.advisor1Kimura, Tatiana Nayara Libório-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/7764426537915981pt_BR
dc.contributor.referee1Tarragô, Andréa Monteiro-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/4644326589690231pt_BR
dc.contributor.referee2Antunes, Heliton Spindola-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/9244970647008323pt_BR
dc.contributor.referee3Santos, Paulo Sergio da Silva-
dc.creator.Latteshttp://lattes.cnpq.br/0456212750170789pt_BR
dc.description.resumoA Leucemia Mieloide Crônica (LMC) é uma doença mieloproliferativa caracterizada pela presença do cromossomo Philadelfia (Ph). O manejo e tratamento dos pacientes com LMC deve ser feito por uma equipe multidisciplinar, incluindo cirurgião dentista, cujo conhecimento do perfil de condição bucal desses pacientes, torna-se importante para uma melhor atuação na promoção da sua saúde bucal e consequentemente impactando também direta ou indiretamente na qualidade de vida desses pacientes. Objetivo: Avaliar a condição de saúde bucal e qualidade de vida de pacientes com LMC diagnosticados em um centro de referência hematológico no Amazonas. Metodologia: Trata-se de um estudo clínico, transversal descritivo/analítico que avaliou as manifestações bucais (MB), CPOD, índice de placa (IP), profundidade de sondagem (PS), Nível de Inserção Clínica (NIC), sangramento a sondagem (SS), diagnóstico periodontal e qualidade de vida relacionado a saúde bucal (OHIP-14), nos pacientes com LMC em até 3 anos de uso de imatinibe. Resultados: : Foram avaliados 36 pacientes, sendo 52,8% do sexo masculino, a mediana de idade foi de 57,5 anos, 94% com ensino básico e 72,2% com renda ≤ 1.212,00 reais. A frequência de MB foi de 5,5% (n=2), sendo uma lesão ulcerada e uma pedicular, índice do CPOD:9,99, sendo 17% (n=6) dos pacientes edêntulos totais (17%) e 77,7% com doença cárie dentária (n=28). Dos pacientes passiveis de avaliação periodontal (n=30) foram observados os seguintes resultados: IP: 57,5% (±27,37), NIC 3,10mm (± 0,35), PS 2,13mm (± 0,28), SS: 49,4% (±28,92) e predominantemente diagnóstico de gengivite 83,3%, sendo 80% gengivite generalizada e 71,4% com periodonto reduzido. A avaliação do OHIP-14 demonstrou impacto fraco na qualidade vida em 88,9% (n=32). Conclusão: A condição bucal de pacientes com LMC em uso de imatinibe até 3 anos mostrou-se insatisfatória considerando a alta frequência de gengivite e cárie dentária, apesar de baixa frequência de alterações em tecidos moles detectadas neste estudo, o que sinaliza a necessidade de vigilância odontológica nesta populaçãopt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references1. Chereda B, Melo J V. Natural course and biology of CML. Ann Hematol. 2015;94(2):107-121. doi:10.1007/s00277-015-2325-z 2. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2 3. Da Silva Santos PS, Coracin FL, Barros JCDA, Dulley FL, Nunes FD, Magalhães MG. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin Transplant. 2011;25(2):325-328. doi:10.1111/j.1399-0012.2010.01283.x 4. Coracin FL, Santos PS da S, Gallottini MHC, et al. Oral health as a predictive factor for oral mucositis. Clinics. 2013;68(6):792-796. doi:10.6061/clinics/2013(06)11 5. Yamagata K, Onizawa K, Yanagawa T, et al. A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(3):237-242. doi:10.1038/sj.bmt.1705429 6. Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC. Support Care Cancer. 2015;23(1):223-236. doi:10.1007/s00520-014-2378-x 7. Stolze J, Vlaanderen KCE, Raber-Durlacher JE, Brand HS. The impact of hematological malignancies and their treatment on oral health-related quality of life as assessed by the OHIP-14: a systematic review. Odontology. 2020;108(3):511-520. doi:10.1007/s10266-019-00479-7 8. Angst PDM, Dutra DAM, Moreira CHC, Kantorski KZ. Periodontal status and its correlation with haematological parameters in patients with leukaemia. J Clin Periodontol. 2012;39(11):1003-1010. doi:10.1111/j.1600-051X.2012.01936.x 9. Angst PDM, Dutra DAM, Manso IS, Moreira CHC, Kantorski KZ. Association between oral health-related quality of life and periodontal status in patients with leukemia. Int Dent J. 2020;70(5):381-387. doi:10.1111/idj.12576 10. Radhi NHA-S, Al-Waheb AM. Estimation of Some Salivary Variables and Oral Health Status of Patients with Chronic Myeloid Leukemia Aged 45 - 55 Years. J Baghdad Coll Dent. 2013;25(Speacial Issue 1):140-145. doi:10.12816/0015129 11. Angst PDM, Maier J, dos Santos Nogueira R, Manso IS, Tedesco TK. Oral health status of patients with leukemia: a systematic review with meta-analysis. 54 Arch Oral Biol. 2020;120(June). doi:10.1016/j.archoralbio.2020.104948 12. Cotti S, Cagetti MG, Muscas G. [The dental study of patients with leukemic pathology. The clinical aspects]. Minerva Stomatol. 1993;42(3):77-86. Accessed May 15, 2020. http://www.ncbi.nlm.nih.gov/pubmed/8321167 13. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(5):S31-S34. doi:10.4103/sja.SJA_543_18 14. Rosenfeld LG, Malta DC, Szwarcwald CL, et al. Reference values for blood count laboratory tests in the Brazilian adult population, national health survey. Rev Bras Epidemiol. 2019;22(Suppl 2):1-13. doi:10.1590/1980-549720190003.supl.2 15. Pias M, Neto G, Ferreira C, Libório-Kimura T. Manifestações bucais da leucemia linfoblástica: estudo clínico em centro de referência hematológico no Amazonas. Rev Port Estomatol Med Dentária e Cir Maxilofac. 2020;61(3):4-10. doi:10.24873/j.rpemd.2020.11.716 16. Tommasi MHM. Diagnóstico Em Patologia Bucal. ELSEVIER; 2014. 17. Oliveira SR, de Azevedo Branco LG, Rocha AL, et al. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review. Clin Oral Investig. 2019;23(12):4371-4382. doi:10.1007/s00784-019-02886-0 18. Klein H PC. Dental caries in American indian children. Publ Hlth Bull. 1937;239:1-54. 19. O’leary TJ, Drake RB, Naylor JE. The Plaque Control Record PLAOUE CONTROL RECORD-PRESENT INDEX PLAQUE CONTROL RECORD the locations where plaque accumulates and in the pa. Jounal Periodontol. 1972;43(1):38. 20. STEFFENS JP, MARCANTONIO RAC. Classificação das Doenças e Condições Periodontais e Peri-implantares 2018: guia Prático e Pontos-Chave. Rev Odontol da UNESP. 2018;47(4):189-197. doi:10.1590/1807-2577.04704 21. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018;89:S159-S172. doi:10.1002/JPER.18-0006 22. De Oliveira BH, Nadanovsky P. Psychometric properties of the Brazilian version of the Oral Health Impact Profile - Short form. Community Dent Oral Epidemiol. 2005;33(4):307-314. doi:10.1111/j.1600-0528.2005.00225.x 23. Baba RK, Vaz MSMG, Da Costa J. Agrometeorological data correction using statistical methods. Rev Bras Meteorol. 2014;29(4):515-526. doi:10.1590/0102-778620130611 24. Vinay K, Yanamandra U, Dogra S, et al. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. Int J Dermatol. 2018;57(3):332-338. doi:10.1111/ijd.13852 55 25. Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg. 2017;43(2):120-124. doi:10.5125/JKAOMS.2017.43.2.120 26. Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib - A case report with clinical implications. Forum Clin Oncol. 2013;4(4):29-33. 27. Myoken Y, Fujita Y, Imanaka R, Toratani S. Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report. Oral Maxillofac Surg. 2021;25(3):421-425. doi:10.1007/s10006-020-00931-x 28. Okubo-Sato M, Yamagata K, Fukuzawa S, et al. Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case. Case Rep Dent. 2021;2021:1-5. doi:10.1155/2021/6621937 29. Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M. Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(4):e208-e211. doi:10.1016/j.oooo.2018.05.008 30. Pesquisa Nacional de Saúde Bucal. Ministério da Saúde. Ouvidoria Do SUS 136 Biblioteca Virtual Em Saúde Do Ministério Da Saúde Resultados Principais.; 2012. doi:10.3310/hta21210pt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.